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Case 1
A 68-year-old Caucasian woman presented with psychosis, orofacial dyskinesias, and memory loss 10 years after a heart transplant for dilated cardiomyopathy. Maintenance immunosuppression at that time included tacrolimus and mycophenolate mofetil. She was initially diagnosed with psychotic depression. MRI revealed subtle right mesial temporal T2-hyperintensity (figure, A). CSF revealed elevations in the white blood cell count (62/μL; normal, <5) and protein level (59 mg/dL; normal, <45 mg/dL). CSF N-methyl-D-aspartate (NMDA) receptor (R) ab (titer 2 [normal, <2]; positive cell-based assay [CBA] ) and Epstein-Barr Virus (EBV) PCR were positive, but HHV-6 PCR was negative. PET-CT body was normal. Additional immunosuppressive treatment with IV methylprednisolone (IVMP) × 12 weeks and rituximab (1 g IV × 2 doses) resulted in resolution of psychosis and memory improvement (34/38-38/38 on Kokmen Short Test of Mental Status [STMS]). She was maintained on cyclosporine and mycophenolate. The modified Rankin Scale (mRS) score was 0 at 24 months from onset.
Case 2
A 61-year-old Caucasian man had subacute memory loss and disorientation 1 month after liver transplant for sclerosing cholangitis. He had received basiliximab and had commenced tacrolimus and mycophenolate mofetil for maintenance immunosuppression. MRI revealed bilateral mesial-temporal T2-signal abnormality (figure, B). The CSF white cell count and protein level were normal, and HHV-6 PCR was negative. Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid Receptor (AMPAR) ab was detected in serum (titer = 30,720; CBA positive) and CSF (titer = 32; CBA positive). CT body was essentially normal. Additional immunosuppression with IVMP (1 g/d for 5 days and then weekly), plasmapheresis (x5), IVIg (0.4 g/kg weekly), rituximab (1 g intravenously × 2 doses), and later oral prednisone (40 mg/d) and a switch from tacrolimus to cyclosporine resulted in improved cognition (26/38-33/38 on Kokmen STMS). Twelve months after onset, his mRS score was 3.
Case 3
A 54-year-old Caucasian woman presented with subacute encephalopathy and bilateral vision loss (left > right) 38 months after HCT for multiple myeloma. She was not taking maintenance immunosuppression but had previously received cyclophosphamide, bortezomib, dexamethasone, and melphalan. MRI showed enhancement of the brainstem, thalamus, and optic nerves (figure, C) consistent with acute disseminated encephalomyelitis (ADEM). CSF revealed an elevated white blood cell count (568/μL; 79% neutrophils) and protein level (117 mg/dL). Serum myelin oligodendrocyte glycoprotein (MOG) ab was positive by fluorescent-activated cell-sorting live CBA (IgG-binding-index 49.7; normal, <2.5). PET-CT body was normal. Five days of IVMP (1 g/d) resolved her encephalopathy, but left eye visual acuity remained 20/400 and the mRS score was 1 at last follow-up, 26 months after onset.
Discussion
We show that AE can occur posttransplant and highlight the potential benefit of additional immunosuppression, particularly antibody/B-cell depleting therapy. Our identification of 3 patients over a 13-year timeframe at our facility and the few previous reported cases suggests that posttransplant AE is rare, but could also reflect AE diagnoses being overlooked in patients receiving immunosuppression.
Each included patient had a neural autoantibody of pathogenic potential with a compatible clinical syndrome (NMDAR: psychosis and orofacial dyskinesia; AMPAR: limbic encephalitis; MOG: ADEM) and improved with additional immunosuppression supporting AE over competing diagnoses. Three case reports of posttransplant anti-NMDAR encephalitis are described. One case occurred 16 months after kidney transplantation for radiation nephropathy preceded by HCT for non-Hodgkin lymphoma 5 ; the 2 other cases were after renal transplant for reflux nephropathy and pyelonephritis, respectively 2, 3 ; all developed AE while taking immunosuppressants (mycophenolate, 3; prednisone, 2; tacrolimus, 1). Similar to our anti-NMDAR encephalitis patient, 2 cases had concurrent EBV infection detected in CSF potentially suggesting a post-infectious AE similar to post-HSV encephalitis or facilitation by blood-brain barrier breakdown with EBV infection or reactivation. Similar to our case of ADEM with MOG Ab, ADEM cases posttransplant are described, but most reports preceded MOG Ab availability.
1 Leucine-rich gliomainactivated 1 (LGI1) ab encephalitis in a child 15 months after HCT for aplastic anemia is also reported. 4 HHV-6 reactivation is associated with limbic encephalitis posttransplant (particularly HCT), but our patients with limbic encephalitis tested negative. Our report suggests that imbalance between B-and T-cell depletion can provoke autoimmunity, similar to how it occurs with congenital (e.g., Di-George syndrome) and iatrogenic (e.g., alemtuzumab) immunodeficiency. 
